stonks4u
Log inSign up free
AIDX logo

AIDX 20/20 Biolabs Inc.

NASDAQ · Medical - Care Facilities · Healthcare

$0.55
+0.00 (+0.16%)

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (C…

Market Cap: $6.74M2020biolabs.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$0.52 – $0.59
52-Week Range
$0.40 – $50.00
Volume
$159.8K
Market Cap
$6.74M
50-Day Avg
$0.58
200-Day Avg
$1.76
Prev Close
$0.55
Open
$0.55

Valuation & Ratios

P/E Ratio
-39.75
EPS
$-0.60
P/B Ratio
-7.76
P/S Ratio
72.96
Debt/Equity
-66.79
Current Ratio
0.60
Dividend Yield
+0.0%
Gross Margin
+29.6%

Returns & Efficiency

Return on Equity
+19.4%
Return on Assets
-0.1%
FCF Yield
-1286.5%
EV/EBITDA
-116.21

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$2.05M$-3.74M$-0.60
2024$1.75M$-5.55M$-1.16
2023$1.42M$-6.39M$-1.34
2022$11.06M$2.19M$0.46
2021$9.62M$2.07M$0.44

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Wed, Sep 2(in 2 weeks)

Consensus estimate $-0.12 per share

0of 1 quarters beat consensus

Typical surprise -180.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, May 20$-0.28 vs $-0.10miss

Estimates and results for AIDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by AIDX officers and directors.

No open-market trades in the recent filings. All 51 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.

51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

AIDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Neutral

    …n as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.

    View source ↗